

TRIMEDYNE REPORTS AN 11% INCREASE IN REVENUES
FOR THE QUARTER ENDED MARCH 31, 2006

FOR IMMEDIATE RELEASE

CONTACT: Jeffrey Rudner
(949) 951-3800, Ext. 285
jrudner@trimedyne.com

May 23, 2006 – Irvine, CA: TRIMEDYNE, INC. (OTCBB “TMED”) today reported an 11% increase in revenues to \$1,545,000 for the quarter ended March 31, 2006, compared to revenues of \$1,392,000 for the same quarter of the prior year.

Net profit was \$83,000 or \$0.01 per share for the current quarter, compared to a net loss of \$24,000 or \$0.00 per share in the prior year quarter. Cost of goods increased to 60% of sales in the current quarter, from 49% in the year ago quarter, due to an increase in the cost of raw materials and overtime wages incurred in increasing production to compensate for the expected loss of manufacturing capacity during the relocation of the Company’s offices and production facilities in May 2006 to a newer building in an adjoining suburb.

Glenn D. Yeik, President of Trimedyne, said, “We are pleased to report a significant increase in sales in the current quarter, compared to the year ago period. While marketing expenses to introduce our new, disposable VaporMAX[®] Side Firing Laser Fiber are expected to rise in the coming months, we anticipate our revenues will increase from sales of this new product, although such cannot be assured.”

Trimedyne manufactures lasers and proprietary fiber optic devices for a variety of minimally invasive surgical procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. Trimedyne has an extensive portfolio of patents covering side-firing technologies. For product, financial and other information, visit Trimedyne's website, <http://www.trimedyne.com>.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-KSB and subsequently filed SEC reports. There is no assurance any new products can be successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.

* * * *